文献速递艾滋病与性传播感染

不同整合酶链转移抑制剂对中国深圳新启动抗逆转录病毒治疗HIV感染者体重指数的影响:真实世界数据分析

Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis.
PubMed 文献 · Clin Infect Dis · 2026-01-01

本研究基于深圳2019年至2023年5月新启动抗逆转录病毒治疗的5102例HIV感染者真实世界数据,采用线性混合模型分析不同ART方案对BMI变化的影响。结果显示含INSTI方案较NNRTI方案在启动后0-0.5年BMI增加多1.27(95%CI 1.14-1.50),0.5-1.5年多0.18(95%CI 0.03-0.33);3TC/DTG方案BMI增加尤为显著,而TDF方案较TAF方案在0.5-1.5年BMI增加少1.07(95%CI -1.34至-0.79)。

要点

  • 含INSTI方案较NNRTI方案在启动ART后早期BMI增加更明显。
  • 3TC/DTG方案较TAF/FTC/EVG/c及TAF/FTC/BIC方案BMI增加更显著。
  • TDF方案较TAF方案显示体重中性或抑制体重的潜在效应。

核心结论

  • 3TC/DTG方案相关的BMI增加尤为突出。
  • TDF显示出体重中性或体重抑制的潜在效应。

研究设计与样本

  • 回顾性队列研究,使用中国深圳2019年至2023年5月新启动ART的≥18岁HIV感染者真实世界数据,共纳入5102例(4771例男性,占93.5%;中位年龄31岁,IQR 26-40)。
  • 采用线性混合模型评估不同ART类别、不同INSTI之间以及含TAF与含TDF方案之间BMI随时间的变化差异。

主要发现

  • 与同期使用NNRTI方案者相比,使用INSTI方案者在ART启动后0-0.5年BMI增加多1.27(95%CI 1.14至1.50),0.5-1.5年BMI增加多0.18(95%CI 0.03至0.33)。
  • 与启动TDF+3TC+DTG、TAF/FTC/EVG/c和TAF/FTC/BIC者相比,使用3TC/DTG者在ART启动后BMI增加更大。
  • 与同期使用含TAF方案者相比,使用含TDF方案者在ART启动后0.5-1.5年BMI增加少1.07(95%CI -1.34至-0.79)。

临床怎么用

  • 新启动ART的HIV感染者选择含INSTI方案时,应关注体重变化,尤其是选用3TC/DTG方案者。
  • 对体重增加风险较高的患者,含TDF方案可能具有体重中性或抑制体重的潜在优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) might be associated with weight gain. The impact of different INSTIs has not been determined, particularly in combination with tenofovir disproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF). METHODS: We conducted a retrospective cohort study using real-world data from people with HIV (PWH) aged ≥18 years who newly started ART between 2019 and May 2023 in Shenzhen, China. We performed linear mixed models to assess whether body mass index (BMI) changes of PWH differed significantly over time across ART classes, among INSTIs, and between TAF- and TDF-containing regimens. RESULTS: A total of 5102 PWH (4771 [93.5%] men; median age 31 [IQR 26-40]) were included in the study. Significant differences in BMI changes were observed among regimens. Compared to PWH who contemporaneously used non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens, people who used INSTI-based regimens 0-0.5 years after ART initiation experienced 1.27 greater BMI gain (95% CI 1.14 to 1.50), 0.5-1.5 years after ART initiation 0.18 greater BMI gain (95% CI 0.03 to 0.33). Compared to PWH who newly started TDF + lamivudine [3TC] + DTG, TAF/emtricitabine [FTC]/EVG/c, and TAF/FTC/BIC, those who used 3TC/DTG experienced greater BMI increases after ART initiation. Compared to people who contemporaneously used TAF-containing regimens, people who used TDF-containing regiments 0.5-1.5 years after ART initiation experienced 1.07 less BMI gain (-1.34 to -0.79). CONCLUSIONS: The increase in BMI associated with 3TC/DTG is particularly prominent. Additionally, TDF showed potential weight-neutral or weight-suppressive effects.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhang L, Wu X, He Y, et al. Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis. Clin Infect Dis. 2026. PMID: 40834233. doi:10.1093/cid/ciaf466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。